Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort

Documenti analoghi

• Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy
  di: Helmneh M. Sineshaw, et al.
  Pubblicazione: (2024)
• Prediction of 5‐year overall survival of diffuse large B‐cell lymphoma on the pola‐R‐CHP regimen based on 2‐year event‐free survival and progression‐free survival
  di: Wan‐Ru Zhang, et al.
  Pubblicazione: (2024)
• Outcomes of the transformation of follicular lymphoma to diffuse large B‐cell lymphoma in the rituximab era: A population‐based study
  di: Wenshuai Zheng, et al.
  Pubblicazione: (2024)
• Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma
  di: Jelena Jelicic, et al.
  Pubblicazione: (2024)
• Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study
  di: Guang‐Liang Chen, et al.
  Pubblicazione: (2024)